Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats

Sharma, Ashish Kumar; Srinivasan, B.P.

doi:10.1016/j.ejps.2009.09.004

Cited by 54 publications

(31 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results revealed that HOMA-IR was significantly higher in diabetic rats than in non-diabetic controls, and QUICKI was significantly lower in diabetic rats than in controls. These results were consistent with the previous reports that diabetic patients had higher values of HOMA-IR [29] and lower values of QUICKI [30]. Interestingly, PSG-1 could ameliorate the HOMA-IR index and QUICKI value, indicating a promising effect of PSG-1 in insulin resistance.…”

Section: Discussionsupporting

confidence: 94%

A newly identified polysaccharide from Ganoderma atrum attenuates hyperglycemia and hyperlipidemia

Zhu

Nie

et al. 2013

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 94%

A newly identified polysaccharide from Ganoderma atrum attenuates hyperglycemia and hyperlipidemia

Zhu

Nie

et al. 2013

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

“…Improved glycemic control delayed DCM in animal models [90]. Strict glycemic control improved stress-induced ventricular dysfunction without CAD in poorly controlled diabetic patients in a large prospective study [91].…”

Section: Prevention and Therapeutic Strategiesmentioning

confidence: 99%

Diabetic cardiomyopathy: where we are and where we are going

Lee

Kim

2017

Korean J Intern Med

133

171

View full text Add to dashboard Cite

The global burden of diabetes mellitus and its related complications are currently increasing. Diabetes mellitus affects the heart through various mechanisms including microvascular impairment, metabolic disturbance, subcellular component abnormalities, cardiac autonomic dysfunction, and a maladaptive immune response. Eventually, diabetes mellitus can cause functional and structural changes in the myocardium without coronary artery disease, a disorder known as diabetic cardiomyopathy (DCM). There are many diagnostic tools and management options for DCM, although it is difficult to detect its development and effectively prevent its progression. In this review, we summarize the current research regarding the pathophysiology and pathogenesis of DCM. Moreover, we discuss emerging diagnostic evaluation methods and treatment strategies for DCM, which may help our understanding of its underlying mechanisms and facilitate the identification of possible new therapeutic targets.

show abstract

“…Moreover, AGEs or high levels of glucose lead to increased extracellular matrix (ECM) production, such as collagen IV, via transforming growth factor ␤1 (TGF-␤1) . To prevent the development and progression of DN, effective therapies directed toward key molecular targets are required (Sharma and Srinivasan, 2009).…”

Section: Introductionmentioning

confidence: 99%

The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy

Lee

Kim

Lee

et al. 2011

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Triple verses glimepiride plus metformin therapy on cardiovascular risk biomarkers and diabetic cardiomyopathy in insulin resistance type 2 diabetes mellitus rats

Cited by 54 publications

References 45 publications

A newly identified polysaccharide from Ganoderma atrum attenuates hyperglycemia and hyperlipidemia

A newly identified polysaccharide from Ganoderma atrum attenuates hyperglycemia and hyperlipidemia

Diabetic cardiomyopathy: where we are and where we are going

The protective effect of Salvia miltiorrhiza in an animal model of early experimentally induced diabetic nephropathy

Contact Info

Product

Resources

About